Literature DB >> 810098

[Treatment by urokinase of myocardial infarction and threatened infarction. Randomised study of 120 cases].

M Brochier, R Raynaud, T Planiol, J P Fauchier, P Griguer, D Archambaud, A Pellois, M Clisson.   

Abstract

Two randomized series of 60 cases of myocardial infarction or menace syndrome have been treated at the acute stage, one by Heparin alone, the other by the combination Urokinase-Heparin. The average dosage was 300 mg Heparin in the first series, of 2,700,000 CTA units of Urokinase combined with 240 mg of Heparin in the second series. After the first 24 hours, equal heparinization was performed in both series up to the third week. Significantly different results were obtained in the two series. They favour Urokinase and concern: -- the disappearance time of pain, -- the course of the arrhythmias and of cardiac failure, -- the regression or limitation of the necrosis q waves and the lesion areas on the electrocardiogram. Finally the 30th-day overall mortality was 13% in the Heparin series and 3% in the myocardial infarction on the way of constitution, or which have done so for less than 24 hours.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810098

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  4 in total

1.  [Coagulation studies and rheological measurements during streptokinase therapy of myocardial infarction (author's transl)].

Authors:  W Theiss; E Volger; A Wirtzfeld; I Keisel; H Blömer
Journal:  Klin Wochenschr       Date:  1980-06-16

2.  Limitation of myocardial infarct size. Present status.

Authors:  S Yusuf; P Sleight
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

Review 3.  Thrombolytic therapy in acute myocardial infarction. A perspective.

Authors:  S Sherry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.